Kevin Puylaert

Kevin Puylaert, listed as senior executive, appears in our data through filings on SOPHiA GENETICS SA shares, published by SEC (Form 4). In total, 13 filings cover trades dated from 19 March 2026 to 5 October 2026.

No open-market purchase appears, only 11 sales worth €5,414. The rest of the record consists of 2 share grants.

The record was last updated on 7 October 2026 with an open-market sale (€1,327) in SOPHiA GENETICS SA. Typically, a trade is published a median of 1 day after it takes place. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.